Abigail Hankin-Wei1, David B Rein2, Alfonso Hernandez-Romieu3, Mallory J Kennedy2, Lisa Bulkow4, Eli Rosenberg3, Monica Trigg3, Noele P Nelson5. 1. Emory University School of Medicine, United States. Electronic address: ahankin@emory.edu. 2. NORC, University of Chicago, United States. 3. Rollins School of Public Health, Emory University, United States. 4. Arctic Investigations Program, NCEZID, U.S. Centers for Disease Control and Prevention, United States. 5. Division of Viral Hepatitis, NCHHSTP, U.S. Centers for Disease Control and Prevention, United States.
Abstract
BACKGROUND: Since 2006, the US Centers for Disease Control and Prevention has recommended hepatitis A (HepA) vaccination routinely for children aged 12-23months to prevent hepatitis A virus (HAV) infection. However, a substantial proportion of US children are unvaccinated and susceptible to infection. We present results of economic modeling to assess whether a one-time catch-up HepA vaccination recommendation would be cost-effective. METHODS: We developed a Markov model of HAV infection that followed a single cohort from birth through death (birth to age 95years). The model compared the health and economic outcomes from catch-up vaccination interventions for children at target ages from two through 17years vs. outcomes resulting from maintaining the current recommendation of routine vaccination at age one year with no catch-up intervention. RESULTS: Over the lifetime of the cohort, catch-up vaccination would reduce the total number of infections relative to the baseline by 741 while increasing doses of vaccine by 556,989. Catch-up vaccination would increase net costs by $10.2million, or $2.38 per person. The incremental cost of HepA vaccine catch-up intervention at age 10years, the midpoint of the ages modeled, was $452,239 per QALY gained. Across age-cohorts, the cost-effectiveness of catch-up vaccination is most favorable at age 12years, resulting in an Incremental Cost-Effectiveness Ratio of $189,000 per QALY gained. CONCLUSIONS: Given the low baseline of HAV disease incidence achieved by current vaccination recommendations, our economic model suggests that a catch-up vaccination recommendation would be less cost-effective than many other vaccine interventions, and that HepA catch-up vaccination would become cost effective at a threshold of $50,000 per QALY only when incidence of HAV rises about 5.0 cases per 100,000 population.
BACKGROUND: Since 2006, the US Centers for Disease Control and Prevention has recommended hepatitis A (HepA) vaccination routinely for children aged 12-23months to prevent hepatitis A virus (HAV) infection. However, a substantial proportion of US children are unvaccinated and susceptible to infection. We present results of economic modeling to assess whether a one-time catch-up HepA vaccination recommendation would be cost-effective. METHODS: We developed a Markov model of HAV infection that followed a single cohort from birth through death (birth to age 95years). The model compared the health and economic outcomes from catch-up vaccination interventions for children at target ages from two through 17years vs. outcomes resulting from maintaining the current recommendation of routine vaccination at age one year with no catch-up intervention. RESULTS: Over the lifetime of the cohort, catch-up vaccination would reduce the total number of infections relative to the baseline by 741 while increasing doses of vaccine by 556,989. Catch-up vaccination would increase net costs by $10.2million, or $2.38 per person. The incremental cost of HepA vaccine catch-up intervention at age 10years, the midpoint of the ages modeled, was $452,239 per QALY gained. Across age-cohorts, the cost-effectiveness of catch-up vaccination is most favorable at age 12years, resulting in an Incremental Cost-Effectiveness Ratio of $189,000 per QALY gained. CONCLUSIONS: Given the low baseline of HAV disease incidence achieved by current vaccination recommendations, our economic model suggests that a catch-up vaccination recommendation would be less cost-effective than many other vaccine interventions, and that HepA catch-up vaccination would become cost effective at a threshold of $50,000 per QALY only when incidence of HAV rises about 5.0 cases per 100,000 population.
Authors: David B Rein; Katherine A Hicks; Kathleen E Wirth; Kaafee Billah; Lyn Finelli; Anthony E Fiore; Thomas J Hoerger; Beth P Bell; Gregory L Armstrong Journal: Pediatrics Date: 2007-01 Impact factor: 7.124
Authors: Philip J Smith; Sharon G Humiston; Edgar K Marcuse; Zhen Zhao; Christina G Dorell; Cynthia Howes; Beth Hibbs Journal: Public Health Rep Date: 2011 Jul-Aug Impact factor: 2.792
Authors: R Monina Klevens; Stephen Liu; Henry Roberts; Ruth B Jiles; Scott D Holmberg Journal: Am J Public Health Date: 2014-01-16 Impact factor: 9.308
Authors: Walter W Williams; Peng-Jun Lu; Alissa O'Halloran; Carolyn B Bridges; David K Kim; Tamara Pilishvili; Craig M Hales; Lauri E Markowitz Journal: MMWR Morb Mortal Wkly Rep Date: 2015-02-06 Impact factor: 17.586
Authors: Noele P Nelson; Mark K Weng; Megan G Hofmeister; Kelly L Moore; Mona Doshani; Saleem Kamili; Alaya Koneru; Penina Haber; Liesl Hagan; José R Romero; Sarah Schillie; Aaron M Harris Journal: MMWR Recomm Rep Date: 2020-07-03